GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. The company is headquartered in Menlo Park, California and currently employs 1,000 full-time employees. The company went IPO on 2024-06-12. The firm is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
Follow-Up Questions
What is the price performance of GRAL stock?
The current price of GRAL is $83.18, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Grail Inc?
Grail Inc belongs to Biotechnology industry and the sector is Health Care
What is Grail Inc market cap?
Grail Inc's current market cap is $2.9B
Is Grail Inc a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for Grail Inc, including 2 strong buy, 4 buy, 4 hold, 0 sell, and 2 strong sell
